

94-04A2.A9A

HEW52:WP51

DEB:HEW.lbj

12/30/97

73 Rec'd PC

05 JAN 1998

PATENT APPLICATION

DOCKET NO.: LKS94-04A2

PCT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Michael J. Briskin, Douglas J. Ringler, Dominic Picarella and Walter Newman

Application No.: 08/875,849

Group Art Unit:

Filed: September 8, 1997

Examiner:

Title: MUCOSAL VASCULAR ADDRESSINS AND USES THEREOF

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Honorable Commissioner of Patents and Trademarks, Washington D.C. 20231	
on 12/31/97	<i>Lisa Jensen</i>
Date	Signature
Lisa Jensen	
Typed or printed name of person signing certificate	

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

This Information Disclosure Statement is submitted:

☐ under 37 CFR 1.129(a), or
(First/Second submission after Final Rejection)

☒ under 37 CFR 1.97(b), or
(Within three months of filing national application; or date of entry of the national stage in international application; or before mailing date of first office action on the merits; whichever occurs last)

☐ under 37 CFR 1.97(c) together with either:

☐ a Statement under 37 CFR 1.97(e), as checked below, or

☐ a \$240.00 fee under 37 CFR 1.17(p), or
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

☐ under 37 CFR 1.97(d) together with:

☐ a Statement under 37 CFR 1.97(e), as checked below, and

☐ a Petition under 37 CFR 1.97(d)(2), and

☐ a \$130.00 petition fee set forth in 37 CFR 1.17(i).

(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

☐ Applicant requests that the attached IDS and cited reference(s) _____ be placed in the application filewrapper.

(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

☐ Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Enclosed herewith is form PTO-1449:

☐ Copies of the cited references are enclosed.

☒ Copies of cited references are enclosed (References AD-AF) except those entered in prior application, U.S. Serial No. 08/523,004 and U.S. Serial No. 08/386,857, and references that are not required to be submitted under 37 CFR 1.98.

☐ The listed references were cited in the enclosed International Search Report in a counterpart foreign application.

Concise Explanation Requirement (non-English references):

☐ The "concise explanation" requirement for reference(s) _____ under 37 CFR 1.98(a)(3) is satisfied by:

☐ the explanation provided on the attached sheet.

☐ the explanation provided in the Specification.

[] submission of the enclosed International Search Report.

[] the enclosed English language abstract.

Method of payment:

[] Enclosed is a check in the amount of \$_____.

[] Please charge Deposit Account 08-0380 in the amount of \$_____.

[] A copy of this Statement is enclosed.

[X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

REMARKS

Recent data generated regarding the protein structure of human MADCAM-1 suggest that the N-terminal amino acid sequence of mature MADCAM-1 (Figure 1) begins at VKPL (valine 23, SEQ ID NO:2), not at QSLQ. Secondly, subsequent to the filing of the subject application on February 12, 1996, Applicants learned that the mutated Fc region used in constructing MADCAM-Ig chimeras contained a Leu → Ala mutation at position 235 rather than at position 234 (Specification, at page 72, line 11 and page 72, line 18).

It is requested that the information disclosed herein be made of record in this application.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Helen E. Wendler
Helen E. Wendler
Attorney for Applicants
Registration No.: 37,964
Telephone: (781) 861-6240
Facsimile: (781) 861-9540

Lexington, Massachusetts 02173

Dated:

December 31, 1997